FDA compliance issues at Mohali and Dadra plants
OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.
SUNPHARMA / Q4-FY24 / risks
Keep the risk register visible.
Sunpharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Elevated R&D and launch costs pressuring margins
Higher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.
Pricing pressure from Stelara biosimilars
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
Currency depreciation in emerging markets
Nigeria forex loss and broader emerging market currency volatility could impact reported revenue and profitability.